Insulet Corporation (NASDAQ:PODD) Receives $343.06 Average Price Target from Brokerages

Key Points

• Insulet Corporation has received an average recommendation of "Moderate Buy" from eighteen brokerages, with 16 buy ratings and 2 hold ratings.
• The average 1-year price target for Insulet's stock is approximately $343.06, with certain analysts establishing targets as high as $380.00.
• Insulet reported earnings per share of $1.17 in its latest quarter, exceeding forecasts and marking a year-over-year revenue growth of 32.9%.

Insulet Corporation (NASDAQ:PODD - Get Free Report) has received an average rating of "Moderate Buy" from the eighteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and sixteen have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $343.0588.

A number of brokerages have recently weighed in on PODD. Raymond James Financial reissued an "outperform" rating and set a $360.00 price target (up from $328.00) on shares of Insulet in a research report on Tuesday, May 27th. Morgan Stanley reiterated an "overweight" rating on shares of Insulet in a report on Thursday, August 7th. JPMorgan Chase & Co. increased their price objective on shares of Insulet from $340.00 to $415.00 and gave the stock an "overweight" rating in a research note on Friday, September 12th. Wells Fargo & Company upped their price objective on shares of Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a research note on Friday, August 8th. Finally, Canaccord Genuity Group lifted their price target on shares of Insulet from $331.00 to $353.00 and gave the company a "buy" rating in a research note on Friday, August 8th.

Insider Buying and Selling at Insulet

In related news, SVP Prem Singh sold 687 shares of the firm's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares of the company's stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the company's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in Insulet by 0.5% in the second quarter. Vanguard Group Inc. now owns 8,708,355 shares of the medical instruments supplier's stock valued at $2,735,991,000 after buying an additional 39,403 shares during the period. Geode Capital Management LLC increased its position in Insulet by 3.1% in the second quarter. Geode Capital Management LLC now owns 1,927,543 shares of the medical instruments supplier's stock worth $603,211,000 after purchasing an additional 58,309 shares during the period. American Century Companies Inc. lifted its stake in Insulet by 34.8% in the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock valued at $302,686,000 after acquiring an additional 297,734 shares in the last quarter. Groupama Asset Managment grew its holdings in Insulet by 0.4% in the 1st quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier's stock valued at $276,728,000 after buying an additional 3,759 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Insulet during the second quarter worth about $324,689,000.

Insulet Trading Down 0.8%

Shares of PODD stock traded down $2.72 on Friday, hitting $332.40. 31,973 shares of the stock traded hands, compared to its average volume of 744,785. The firm's 50-day moving average price is $316.00 and its two-hundred day moving average price is $295.09. Insulet has a twelve month low of $225.37 and a twelve month high of $353.50. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The stock has a market capitalization of $23.40 billion, a PE ratio of 101.03, a PEG ratio of 2.75 and a beta of 1.36.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. The firm had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.Insulet's quarterly revenue was up 32.9% on a year-over-year basis. During the same period last year, the business posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, analysts anticipate that Insulet will post 3.92 EPS for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.